Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
NCT07137390 · M.D. Anderson Cancer Center · PHASE1/PHASE2 · withdrawn · last registry update 2026-03-11 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “0 participants enrolled” | Open Targets' class: insufficient enrollment | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-03Also stopped (terminated): Peking University Cancer Hospital & Institute, KN046 + regorafenib (NCT05985109)
- 2026-09-11Results posted on the registry: Memorial Sloan Kettering Cancer Center, Regorafenib (NCT02023333)
- 2026-08-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-08-26Also stopped (terminated): Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-07-28Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M07D1 + Regorafenib (NCT07730489)
- 2026-07-23Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., IBI363 + bevacizumab + Investigator's choice of therapy (NCT07722494)
- 2026-07-22Results posted on the registry: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2026-07-06Results posted on the registry: Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-07-06Also stopped (terminated): Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-06-16Results posted on the registry: University of Southern California, Pembrolizumab + Regorafenib (NCT03657641)
- 2026-05-29Results posted on the registry: National Cancer Institute (NCI), Paclitaxel + Nilotinib (NCT05185947)
- 2026-03-19Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., TQB2102 Injection + Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets (NCT07483684)
- 2026-02-25Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07223567)
- 2026-02-03Phase 3 first posted: Shanghai JMT-Bio Inc., JSKN003 + Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (NCT07384377)
- 2026-01-20Also stopped (terminated): Anwaar Saeed, Regorafenib + Pembrolizumab (NCT06006923)
- 2025-12-03Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Trametinib (NCT03377361)
- 2025-09-17Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05064059)
- 2025-09-17Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05600309)
- 2025-08-21Phase 3 first posted: Shanghai JMT-Bio Inc., JMT101 + Irinotecan (NCT07134205)
- 2025-07-18Results posted on the registry: Institut du Cancer de Montpellier - Val d'Aurelle, Regorafenib + Irinotecan (NCT03829462)
- 2025-05-28Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Trifluridine/Tipiracil + Regorafenib + Trifluridine/tipiracil + bevacizumab (NCT06992648)
- 2025-03-30Also stopped (terminated): UNICANCER, Regorafenib then Trifluridine/Tipiracil + Trifluridine/Tipiracil then Regorafenib (NCT04450836)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision